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ABSTRACT
Objectives: The aim of this study was to develop an in vitro - in vivo correlation (IVIVC) for the prepared Camptothecin (CPT)-loaded polymeric 
nanoformulation.
Methods: In this study, CPT-loaded polymeric nanoformulation was prepared by nanoprecipitation method using containing poly (methacrylic acid-
co-methyl methacrylate) (polymer), poloxamer 188 (non-ionic surfactant), and β-cyclodextrin (stabilizer). In vitro release rate data were obtained 
from prepared polymeric nanoformulation using the USP apparatus type 2. A single-dose, crossover pharmacokinetic study for the nanoformulation 
was carried out in six albino rats. These data were used as the basis for the IVIVC model development.
Results: The plasma concentration of CPT was estimated by high-performance liquid chromatography. The pharmacokinetic parameters were 
calculated from the plasma concentration of CPT and time data. Furthermore, the deconvolution of the in vivo concentration-time data was performed 
using Wagner–Nelson method to estimate the in vivo drug release profile.
Conclusion: Therefore, a level A IVIVC was developed for CPT-loaded polymeric nanoformulation between dissolution percentage and intestinal 
absorption in rats. The simplest way to demonstrate a correlation is to plot the percentage absorbed in vivo versus the percentage released in vitro at 
the same time.
Keywords: Camptothecin, In vitro - in vivo correlation, Wagner–Nelson, Dissolution, Pharmacokinetics.
INTRODUCTION
Camptothecin (CPT) naturally occurring quinolone alkaloids shows 
a significant anticancer activity with a broad spectrum of human 
malignancies. CPT is an inhibitor of the DNA-replicating enzyme 
topoisomerase I which is believed to act by stabilizing a topoisomerase 
I-induced single strand break in the phosphodiester backbone of DNA, 
thereby preventing relegation [1]. Despite of its promising activity, 
the clinical applications are hampered by its poor water solubility, 
low stability in physiological medium, severe systemic toxicity, and 
low antineoplastic activity [2]. Accordingly, a novel drug delivery 
system is imperative to overcome the internal defects. In recent years, 
nanostructured materials such as nanoparticles have been considered 
as potential carriers for hydrophobic drug delivery that may resolve the 
aforementioned problems [3].
A key goal in the pharmaceutical development of dosage forms is a good 
understanding of the in vitro and in vivo performance of the dosage 
forms. One of the challenges of biopharmaceutics research is correlating 
in vitro drug release information of drug formulations to the in vivo 
drug profiles [4]. In vitro - in vivo correlations (IVIVC) play an important 
role in reducing the drug development time and optimization of the 
formulation. A good correlation is a tool for predicting in vivo results 
based on in vitro data [5]. The IVIVC can be used in the development of 
new pharmaceuticals to reduce the number of human studies during 
the formulation development [6].
The IVIVC is a mathematical relationship between in vitro properties of 
a dosage form with its in vivo performance. For oral dosage forms, the 
in vitro release is usually measured and considered as dissolution rate. 
The relationship between the in vitro and in vivo characteristics can 
be expressed mathematically by a linear or nonlinear correlation [7]. 
However, the plasma concentration cannot be directly correlated to 
the in vitro release rate; it has to be converted to the in vivo release 
or absorption data, either by pharmacokinetic compartment model 
analysis or by linear system analysis [6].
IVIVC definitions
Food and Drug Administration (FDA) definition of IVIVC (FDA, 
1997)
The IVIVC has been defined by the FDA as “a predictive mathematical 
model describing the relationship between an in vitro property of a 
dosage form and an in vivo response.”
In general, the in vitro property is the rate or extent of drug dissolution 
or release while the in vivo response is the plasma drug concentration 
or amount of drug absorbed [8]. However, the correlation between the 
in vitro dissolution rate and in vivo absorption rate does not always exit. 
Nevertheless, making an accurate prediction of in vivo performance 
based on in vitro dissolution is not a straight forward process and many 
traps could involuntarily bias the predictions. Thus, the main objective 
of the IVIVC is to serve as a surrogate for in vivo bioavailability and to 
support biowaivers [9].
Levels of IVIVC
There are four levels of IVIVC that have been described in the FDA 
guidance, which include levels A, B, C, and multiple C. The concept of 
correlation level is based on the ability of the correlation to reflect 
the complete plasma drug level-time profile which will result from 
administration of the given dosage form [10].
Level A correlation
The IVIVC that correlates the relationship between the entire in vitro 
and in vivo profiles for its regulatory relevance and is called the level A 
correlation. This level of correlation is generally linear and represents a 
point-to-point relationship between in vitro dissolution rate and in vivo 
input rate of the drug from the dosage form [6,11].
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The purpose of level A correlation is to define a direct relationship 
between in vivo data such that measurement of in vitro dissolution 
rate alone is sufficient to determine the biopharmaceutical rate of 
the dosage form. In this context, the model refers to the relationship 
between the in vitro dissolution of an extended release dosage form and 
an in vivo response such as plasma drug concentration or amount of 
drug absorbed.
Level B correlation
A level B IVIVC is based on the principles of statistical moment analysis. 
In this level of correlation, the mean in vitro dissolution time of the 
product is compared to either mean in vivo residence time or the mean 
in vivo dissolution time. The level B correlation does not uniquely reflect 
the actual in vivo plasma level curves because a number of different 
in vivo curves will produce similar mean residence time values [6,11].
Level C correlation
A Level C correlation relates a single dissolution time point (t50%, t90%, 
etc.) to a pharmacokinetic parameter such as area under the curve 
(AUC), tmax, or Cmax. This is the weakest level of correlation relationship 
between absorption, and dissolution is established since it does not 
reflect the complete shape of plasma drug concentration-time curve, 
which is the critical factor that defines the performance of a drug 
product [6,11].
Multiple level C correlations
This level refers to the relationship between one or more 
pharmacokinetic parameters of interest (Cmax, AUC, or any other suitable 
parameters) and the amount of drug dissolved at several time point of 
dissolution profile. Multiple point level C correlation may be used to 
justify biowaivers provided that the correlation has been established 
over the entire dissolution profile with one or more pharmacokinetic 
parameters of interest [6,11] (Table 1).
METHODS
Formulation of CPT-loaded polymeric nanoparticles
About 100 mg of poly (methacrylic acid-co-methyl-methacrylate) 
polymer with 10 mg of CPT were dissolved in 10 ml of dimethyl sulfoxide. 
The prepared organic phase was transferred at once into 500 ml beaker 
containing 50 mg of β-cyclodextrin, 100 mg of poloxamer 188, and 20 ml 
of distilled water under mechanical stirring (Remi, India) at 500 rpm. 
Polymeric nanoparticles were formed spontaneously, but the stirring 
process is continued for 50 minutes to aid the size reduction and to 
evaporate the residual solvents (Table 2). The fabrication experiments 
were performed in triplicate.
In vitro evaluation
In vitro drug release of CPT from polymeric nanoparticles was evaluated 
by dialysis bag diffusion technique. The prepared CPT-loaded polymeric 
nanoformulation (weight equivalent to 10 mg of drug) was placed in a 
cellulose dialysis bag (cutoff 12 000; HIMEDIA, Mumbai, Maharashtra, 
India) and sealed at both ends. The dialysis bag was immersed in the 
receptor compartment containing dissolution medium maintained 
at 37°C±0.5°C with a rotating speed of 100 rpm [12]. The release 
characteristic of CPT from the prepared nanoparticle formulation was 
investigated using USP dissolution apparatus 2 (Electrolab, Mumbai, 
Maharashtra, India). To achieve simulated gastrointestinal transit 
condition, the release profile of nanoformulation was studied with 
the dissolution medium of changing pH at various time intervals. 
Initially, the dissolution medium was maintained at pH 1.2 with 350 ml 
of 0.1N HCl for 0-2 hrs. At the end of the second hour, the pH of the 
dissolution medium was raised to 4.5 by the addition of 250 ml of 
solution composed of 3.75 g of KH2PO4 and 1.2 g of NaOH and the total 
volume of dissolution medium was 600 ml. At the end of the 4th hour, 
pH of medium was raised to 7.4 by addition of 300 ml of phosphate 
buffer concentrate (2.18 g of KH2PO4 and 1.46 g of NaOH in distilled 
water) [13,14]. At predetermined time intervals, 5 ml of sample was 
withdrawn and replaced with fresh dissolution media. The collected 
samples were filtered through 0.45 µm membrane filter (Millipore). 
After appropriate dilution, the concentration of drug in the sample was 
analyzed using high-performance liquid chromatography (HPLC).
In vivo evaluation
In vivo evaluation of the prepared CPT-loaded polymeric 
nanoformulations was assessed in rats randomly distributed into two 
groups of six rats in each group. Rats in group 1 received pure CPT 
suspension (5 mg/kg), and group 2 rats received CPT encapsulated 
polymeric nanoformulation (5 mg/kg) with the help of cannula 
after anesthetizing for a very short period with diethyl ether. The 
animal experiment was performed as per the protocol approved 
by the Institutional Animal Ethics Committee (160/1999/CPCSEA; 
Proposal Number 975; Approved on 07.02.2013). The blood samples 
(0.5 ml) were collected from the retro-orbital plexus under mild 
ether anesthesia into heparinized microcentrifuge tubes (containing 
20 μl of 1000 IU heparin/ml of blood) at 0 minute 1, 2, 4, 8, 10, 12, 
24, and 36 hrs after drug administration. After each sampling, 1 ml of 
dextrose-normal saline was administered to prevent changes in the 
central compartment volume and electrolytes. Plasma samples were 
obtained by centrifugation of each blood sample at 3000 rpm at 4°C for 
10 minutes and was stored at −20°C, and the concentration of drug was 
determined by HPLC analysis [15]. The pharmacokinetic parameters 
such as area under the plasma concentration-time curve (AUC0-t), 
maximum plasma concentration (Cmax), and the time taken to reach the 
maximum plasma concentration (Tmax) were determined from plasma 
concentration data.
IVIVC
The level A IVIVC, the point-to-point relationship between in vitro 
dissolution and the in vivo input rate, was studied. The procedure of 
developing an IVIVC consisted of the following steps: Calculation of 
cumulative in vitro dissolution rate, calculation of cumulative in vivo 
absorption rate from concentration-time data obtained by Wagner–
Nelson method and modeling the relationship between in vivo 
absorption rate and in vitro dissolution rate.
Wagner–Nelson is a mass equation which allows calculation of the 
absorption in the case of the one compartment model as stated in 
guidelines [8,16]. This equation uses observed concentrations (C[t]), 
AUC, and apparent elimination rate constant determined from the data 










This equation exhibits a domain from 0% to 100%. In some cases, 
when the Wagner–Nelson equation is used, a flip-flop model could 
exist, especially in case of sustained release formulations where the 
absorption rate is much lower than the elimination rate. In this case, the 
terminal decreasing of the plasma concentration curve, which normally 
reflects the elimination rate (ke), becomes a reflection of actual 
absorption rate (ka), while the initial increasing part of the curve, which 
normally reflects the absorption rate (ka), is the actual representation 
of the elimination rate (ke).
Table 1: Various parameters used in IVIVC depending on the level
Level A B C




Disintegration time, time 
to have 10%, 50%, 90% 
dissolved, dissolution rate, 
dissolution efficiency






Cmax, Tmax, Ka, time to have 
10%, 50%, 90% absorbed, 
AUC (total or cumulative)
IVIVC: In vitro - in vivo correlation, AUC: Area under the curve, MDT: Mean 
dissolution time, MAT: Mean absorption time, MRT: Mean residence time
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However, the simplest way to demonstrate a correlation is to plot the 
percentage absorbed in vivo (obtained by Wagner–Nelson Method) 
versus the percentage released in vitro at the same time [8].
RESULTS AND DISCUSSION
Fabrication of plain and CPT-loaded polymeric nanoparticles
CPT-loaded poly (methacrylic acid-co-methyl-methacrylate) 
nanoparticles were prepared based on the principle of 
nanoprecipitation under the influence of stirring. In nanoprecipitation 
method, the solvent stream contains CPT and poly (methacrylic 
acid-co-methyl-methacrylate) in water miscible organic solvent 
dimethyl sulfoxide, and antisolvent stream contains poloxamer 188 
as a surfactant and β-cyclodextrin as a stabilizer in water. Addition of 
solvent stream into the antisolvent stream results in the miscibility 
of dimethyl sulfoxide with water, which leads to the increase in the 
polarity of dimethyl sulfoxide, which in turn decreases the solubility 
of the polymer. However, nucleation of polymer gets initiated when 
the equilibrium concentration surpasses the solubility threshold of 
the polymer. Stirring process aid the size reduction of polymer at the 
initial stage but in the later stages, anionic nature of polymer provided 
anionic charge to the nanoparticle surface and higher number of likely 
charged nanoparticles repels each other and creates an electrostatic 
repulsive force and maintains the nanoparticles in Brownian motion, 
which is expected to overcome the Van der Waals attractive force 
arising from induced dipole-dipole interaction between nanoparticles 
and gravitational force, thereby stabilize the nanoformulation by 
preventing the aggregation.
In vitro dissolution profiles of the prepared CPT-loaded polymeric 
nanoparticles are presented in Fig. 1. The prepared CPT-loaded 
polymeric nanoparticles showed 98.22 % of drug release. In vitro drug 
release from the drug-loaded polymeric nanoparticles was assessed 
in simulated gastrointestinal conditions. The pH condition used was 
pH 1.2 for 2 hrs (stomach), pH 4.5 for 2 hrs (duodenum) followed by 
pH 7.4 (distal ileum and colon) for the remaining period of the study 
using a USP dissolution test apparatus (Apparatus type 2). The drug 
release was found to be less than 5% up to 4 hrs and the drug release 
increased when the pH of the medium was adjusted to 7.4.
The plasma concentration-time profiles for the CPT-loaded polymeric 
nanoparticles are presented in Table 3. The pharmacokinetic 
parameters of the mean concentration-time profile of the prepared 
CPT-loaded polymeric nanoparticles were estimated.
The pharmacokinetic profiles of the prepared CPT-loaded polymeric 
nanoformulations showed a significant difference from the 
pharmacokinetic profiles of free CPT suspension. The AUC of CPT 
in rats treated with nanoparticles was 1826.52±76 ng/h/ml, which 
was significantly improved (***p<0.001) compared with that of free 
CPT suspension (187.80±58 ng/h/ml). The improved AUC of CPT 
nanoparticles is due to more uptake of CPT in the intestine from the 
nanoformulation.
The feasibility of developing the level A correlation for CPT-loaded 
polymeric nanoparticles formulations was evaluated by plotting the 
percentage of fraction dissolved in vitro with respect to the percentage 
of fraction absorbed in vivo (Fig. 2). There was a good correlation 
between the in vitro and in vivo cumulative release profiles. A consistent 
Table 2: Fabrication of Camptothecin-loaded polymeric nanoparticles
Trials A (mg) B (mg) C (mg) D (mg) E (ml) F (ml) G (min) H (rpm) J K L
1 10 100 50 100 10 20 50 500 At once Or. to Aq. Blade
A: Concentration of drug, B: Concentration of poly (methacrylic acid-co-methyl-methacrylate), C: Concentration of β‑cyclodextrin, D: Concentration of Poloxamer 188, 
E: Volume of organic phase, F: Volume of aqueous phase, G: Stirring time, H: Stirring speed, J: Mode of addition, K: Process, L: Stirring mode, Or.: Organic phase, 
Aq.: Aqueous phase
Table 3: Pharmacokinetic parameters of Camptothecin after 
oral administration of free drug and nanoformulation (5 mg/kg) 
in rats




Tmax (h) 0.5±0.02 12±0.42***
Cmax (ng/ml) 135.15±12.56 197.75±16.25***
AUC (ng/hrs/ml) 187.80±58.26 1826.52±76.18***
AUMC (ng/hrs/ml) 286.25±24.26 22873.3±85.12***
t1/2 (h) 0.86±0.03 3.26±0.25***
Ke (h−1) 0.95±0.02 0.08±0.01***
MRT (h) 1.52±0.25 20.07±1.42***
Cl (ml/h/kg) 0.02±0.03 0.001±0.02***
The values are represented as mean±SD; (n=6); ***Indicates that the result is 
highly significant at p<0.001. SD: Standard deviation, IVIVC: In vitro - in vivo 
correlation, MRT: Mean residence time, AUMC: Area under the first moment curve
Fig. 1: In vitro release profile of Camptothecin-loaded polymeric 
nanoparticles. The values are represented as mean±standard 
deviation (n=6)

























Percentage absorbed (In vivo)
Series1
Linear (Series1)
Fig. 2: In vitro - In vivo correlation of Camptothecin-loaded 
polymeric nanoparticles
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correlation (r2>0.965) was observed between in vitro and in vivo profiles. 
The correlation quality depends solely on the quality of the data. The 
proposed method demonstrates a schema for developing IVIVC using 
data from biostudies conducted during formulation development.
CONCLUSION
As the objective of the study is to develop the IVIVC mathematical model 
to describe the relationship between the in vitro fraction dissolved and 
in vivo fraction absorbed, the level A IVIVC was developed and showed a 
best-fit relationship between in vitro dissolution and in vivo absorption 
data for CPT-loaded polymeric nanoparticles formulation.
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